Status:
RECRUITING
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study
Lead Sponsor:
Catharina Ziekenhuis Eindhoven
Collaborating Sponsors:
Eindhoven University of Technology
Roche BV Netherlands
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Despite scientific evidence, use of liquid biopsy (LB) in diagnosis and monitoring of lung cancer (LC) is limited since it requires major changes in diagnostic and care pathways. Analyzing tumor marke...
Detailed Description
RATIONALE: Despite scientific evidence, use of liquid biopsy (LB) in diagnosis and monitoring of lung cancer (LC) is limited since it requires major changes in diagnostic and care pathways. Analyzing ...
Eligibility Criteria
Inclusion
- Aged 18 or above and suspected of having lung cancer
Exclusion
- Presence of another malignant tumor, i.e. diagnosed with a tumor in the past 5 years
Key Trial Info
Start Date :
October 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06105177
Start Date
October 31 2023
End Date
October 1 2026
Last Update
September 19 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland Medical Center
Heerlen, Limburg, Netherlands, 6419PC
2
Maastricht University Medical Center
Maastricht, Limburg, Netherlands, 6229HX
3
Catharina Ziekenhuis Eindhoven
Eindhoven, North Brabant, Netherlands, 5623EJ
4
St. Anna Ziekenhuis
Geldrop, North Brabant, Netherlands, 5664EH